From secondary to primary prevention of progressive renal disease: The case for screening for albuminuria  by De Jong, Paul E. & Brenner, Barry M.
Kidney International, Vol. 66 (2004), pp. 2109–2118
PERSPECTIVES IN RENAL MEDICINE
From secondary to primary prevention of progressive renal
disease: The case for screening for albuminuria
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From secondary to primary prevention of progressive renal dis-
ease: The case for screening for albuminuria. Many subjects
nowadays present with end-stage renal failure and its attendant
cardiovascular complications without known prior renal dam-
age. In this report we review the evidence available to strongly
suggest that the present practice of secondary prevention in
those with known prior renal disease should be extended to
primary prevention for those subjects in the general population
who are at risk for progressive renal failure, but who had never
suffered from a primary renal disease. We show that such sub-
jects can be detected by screening for albuminuria. Elevated
urinary albumin loss is an indicator not only of poor renal, but
also of poor cardiovascular prognosis. In addition to diabetic
subjects who are at risk for albuminuria, we also show that
hypertensive, obese, and smoking subjects are more suscepti-
ble. We suggest that therapies that have been shown to lower
albumin excretion, such as ACE inhibitors, angiotensin II re-
ceptor antagonists, and statins be started early in such patients
to prevent them from developing clinical renal disease and its
attendant cardiovascular complications.
Historically, nephrology expanded greatly after the de-
velopment of the artificial kidney and the introduction
of renal transplantation. Due to the great demand for
renal replacement therapy, little effort was given to pri-
mary or secondary prevention of progressive renal dis-
ease. Fortunately, however, in the last decade much has
been achieved in secondary prevention in subjects who
had been diagnosed with already established renal dam-
age due to glomerular or tubulointerstitial renal diseases.
This secondary prevention aimed at preventing progres-
sive renal function loss in these patients with prior renal
disease. Low-protein diets [1] (although in clinical prac-
tice difficult to achieve), and antihypertensive agents, in
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general [2], but angiotensin-converting enzyme (ACE)
inhibitors [3, 4, 5] and angiotensin II receptor antago-
nists [6, 7], in particular, appeared especially effective in
retarding a further progressive renal function decline. Re-
cent, yet not thus far confirmed data suggest that the use
of lipid-lowering agents [8], weight reduction [9], and ces-
sation of smoking [10] may also be beneficial in secondary
prevention. With such interventions it is possible to re-
tard the progressive decline in renal function: the slope
of glomerular filtration rate (GFR) over time becomes
less steep, and the time elapsing before renal replace-
ment therapy is started has been extended significantly.
Some reports even document the reversal of prior renal
function decline [11, 12].
Despite successes in slowing progression after renal in-
jury has already occurred, we are still faced with increas-
ing numbers of patients requiring renal replacement ther-
apy. The increasing demand for these services is partly
related to the fact that dialysis and renal transplant tech-
niques have improved and are now extended to those
who are elderly or suffer systemic diseases (i.e., diabetes
and generalized atherosclerosis). Whereas diabetes now
constitutes the major cause of end-stage renal disease
(ESRD) in many national registries, it should be noted
that the number of patients reaching ESRD without a re-
nal diagnosis is also increasing dramatically. Besides dia-
betes, the importance of generalized atherosclerosis and
hypertension to insidious loss of renal function, therefore,
cannot be neglected [13].
In this paper we will (1) consider the mechanisms
underlying the progressive decline in renal function
observed in subjects with preexisting renal disease.
Cognizant of these mechanisms, we will (2) examine the
factors likely to be responsible for initiating loss of renal
function in the general population; (3) review the options
available to detect subjects at risk for early loss by screen-
ing for albuminuria; and (4) consider whether strategies
that have been proven effective in secondary prevention
will also be effective as primary prevention, that is, pre-
vention of progressive renal function loss in those not
known to have prior renal disease, and at a time when
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renal function loss is not yet manifest. Such preventive
efforts should ultimately improve long-term health and
greatly reduce the economic burden related to renal re-
placement therapy. Considering the evidence available,
we believe it is essential for large ongoing and future
epidemiologic studies that focus on risk factors for, and
treatment of, cardiovascular disease to add albuminuria
measurements to their protocol. Additionally, it would be
of great benefit for optimizing cardio- and renoprotective
therapies in primary health care to include albuminuria
measurements in the routine follow-up of patients.
MECHANISMS UNDERLYING PROGRESSIVE
LOSS OF RENAL FUNCTION
At present, much is known about the mechanisms
underlying the progressive decline in renal function in
patients with known renal disease. It has been well doc-
umented that the hemodynamic adaptations of glomeru-
lar hypertension and hyperfiltration in remnant nephrons
(i.e., those nephrons not damaged by the initiating re-
nal disease) ultimately prove detrimental. They suffer
progressive glomerulosclerosis, a process that sets into
motion a vicious cycle of nephron loss. The more initial
nephrons lost, the more the hemodynamic burden to the
remaining ones [14]. The ensuing protein leakage through
these affected glomeruli results in enhanced tubule pro-
tein reabsorption, which initiates progressive tubule
atrophy and interstitial fibrosis [15]. Clinically, the most
important factors promoting this final common pathway
of progressive nephron loss are hypertension [16], pro-
teinuria [17], hyperlipidemia [18], and genetic factors,
such as race [19] and ACE gene polymorphism [20]. Other
factors such as obesity [21], smoking [22], low birth weight
[23], male gender [24], and high salt intake [25] are also
likely to be associated with a worse outcome in subjects
with preexisting renal disease.
DOES HYPERFILTRATION ALSO OCCUR IN
HEALTHY KIDNEYS, AND WHAT IS THE
CONSEQUENCE?
The potential for hyperfiltration also occurs in other
“physiologic” circumstances, such as congenital reduc-
tion in nephron number, sickle cell anemia, and follow-
ing uninephrectomy (i.e., after kidney donation). Does
glomerular hyperfiltration also explain the GFR decline
in normal aging? In the normal population, GFR de-
creases from the age of 30 by about 0.8 mL/min/year
[26]. Assuming that a 30-year-old subject has a normal
GFR of about 120 mL/min, his/her GFR will be about
70 mL/min at the age of 80. A renal biopsy in a kidney
from that 80-year-old person will typically reveal some
atrophic glomeruli with tubule atrophy, other glomeruli
showing signs of glomerulosclerosis, and still others show-
ing glomerular enlargement and hypertrophy. It has been
shown that the age-related decline in renal function, as
well as in renal cortical thickness is accelerated in cases
of generalized atherosclerosis [27]. If an elevated GFR
by itself bears the risk of later progressive renal func-
tion loss, we should question whether screening for hy-
perfiltration would be of help to detect subjects at risk.
Screening for glomerular hyperfiltration with accurate
renal function studies is, however, not feasible in popu-
lation studies. Measuring creatinine clearance is also dif-
ficult to perform in population studies, and an elevated
creatinine clearance in a single subject does not allow in-
vestigators to conclude that hyperfiltration exists in that
subject because of possible inaccuracies in 24-hour urine
collections. Finally, indirect GFR estimates such as the
Modification of Diet in Renal Disease (MDRD) formula
or the Cockroft-Gault formula have never been tested in
the range of normal to elevated GFRs. Thus, the detec-
tion of glomerular hyperfiltration in population studies is
difficult to achieve.
With regard to the relationship between initial
glomerular hyperfiltration and subsequent loss of renal
function, we should learn from the experience in diabetes
mellitus, especially type 1 diabetes. This is the condition
in which the course of GFR in the long run is best stud-
ied, and in which the relation between hyperfiltration and
albuminuria has been well established. If such an asso-
ciation also holds true for the general population, the
screening for microalbuminuria may be appropriate.
ALBUMINURIA AS AN INDICATOR OF
GLOMERULAR HYPERFILTRATION
It is well known that glomerular hyperfiltration exists
in the initial years after onset of hyperglycemia both in
type 1 [28, 29] and type 2 diabetes [30, 31]. This increase
in GFR is related to both a rise in renal plasma flow and
in filtration fraction, caused by afferent, but not efferent,
vasodilatation and increased glomerular capillary pres-
sure. Without treatment, this phase continues for about a
decade before urinary albumin loss commences and rises
to the level of microalbuminuria (defined as urinary al-
bumin excretion of 20–200 lg/min or 30–300 mg/day). At
this time, GFR declines to normal and then subnormal
levels, and ultimately progresses to end-stage renal fail-
ure. This latter phase coincides with a further increase
in albuminuria, often to more than 2 g/day. This longi-
tudinal pattern of changes in GFR and albuminuria in
type 1 diabetes is illustrated in Figure 1 [32]. Data on
the time course of GFR and albuminuria in type 2 dia-
betes are sparse. It has been shown that GFR increases
during follow-up in Pima Indians with impaired glucose
tolerance and recently detected type 2 diabetes (at the
time where there is not yet albuminuria), whereas GFR is
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Fig. 1. The longitudinal data on glomerular filtration rate (GFR) and
urinary albumin excretion in type 1 diabetes, showing that initially hy-
perfiltration is present. Next, in time, albumin excretion starts to rise. At
that time, GFR starts to drop, to ultimately reach the level of end-stage
renal failure and macroproteinuria (derived from [32]). The stippled
area in the GFR plot indicates the normal value; the hatched area in
the albuminuria plot refers to the microalbuminuria range.
stable during the period of microalbuminuria and dimin-
ishes as macroproteinuria develops [33].
The experience in diabetes can be used as a model
to study the impact of an increased albumin excretion
in nondiabetic subjects, as well. Indeed, a similar asso-
ciation between albuminuria and creatinine clearance
was observed in a large cohort of about 8000 nondia-
betic subjects of the general population. The presence of
albuminuria in the high normal range (15–30 mg albu-
min per day), or the so-called “micro” albuminuria range
(30–300 mg per day) was associated with glomerular hy-
perfiltration [34]. In contrast, the subjects with macropro-
teinuria (>300 mg per day) showed an impaired GFR.
These data indicate that the presence of an elevated al-
bumin excretion can be used to identify subjects with
glomerular hyperfiltration. Although these latter data are
cross-sectional, they are in agreement with the longitu-
dinal data shown in Figure 1. The emphasis we give to
the relation between glomerular hyperfiltration and an
increased urinary albumin excretion does not imply that
hyperfiltration is the only mechanism of albuminuria. The
scope of this review, however, is not to extensively re-
Table 1. Risk factors associated with elevated albuminuria
Nonmodifiable Modifiable
Well documented Likely
Race/ethnicity Diabetes Hyperlipidemia
Male gender Hypertension High salt (and protein) diet
Older age Obesity Oral contraceptives
Low birth weight Smoking Hormone replacement therapy
view the various pathohysiologic mechanisms underly-
ing glomerular albumin leakage and tubular handling of
proteins, which are well studied in primary glomerular
diseases. To that purpose, we refer to extensive in-depth
reviews that have been published recently [35, 36].
In diabetes, prevention of microalbuminuria to
macroalbuminuria is considered as secondary preven-
tion, and prevention of normoalbuminuria to microal-
buminuria can be considered as primary prevention. In
line with the pattern observed in Figure 1, it could thus be
argued that the detection of a subject with glomerular hy-
perfiltration (with a shift from normo via “high-normal”
to microalbuminuria) makes him/her suitable for pri-
mary prevention. In contrast, detecting him/her at the
time when glomerular hyperfiltration is no longer man-
ifest (that is, when microalbuminuria shifts to macroal-
buminuria) makes him/her suitable only for secondary
prevention. What conditions then, besides diabetes, are
associated with increased urinary albumin excretion, and
what is the evidence that these conditions are also asso-
ciated with glomerular hyperfiltration?
FACTORS ASSOCIATED WITH ELEVATED
URINARY ALBUMIN EXCRETION
Table 1 summarizes the various risk factors associ-
ated with albuminuria. They are grouped as either non-
modifiable or modifiable by therapeutic approaches, and
further subdivided as to whether the risk has been well
documented or is likely, when adequately studied, to
prove to be associated. It is evident that many of the re-
ported risk factors overlap with those already known to
be associated with progression of established renal dis-
ease. Indeed, most of the factors mentioned have also
been shown in diabetes to favor the development of
microalbuminuria. Discussed below is the available ev-
idence that these various risk factors contribute to both
hyperfiltration and albuminuria.
Nonmodifiable risk factors associated with a higher
urinary albumin excretion
Various reports have documented a higher prevalence
of an elevated albumin excretion in specific ethnic groups
[37, 38]. Also, male gender [39, 40], older age [40, 41], and
low birth weight [38, 39, 42] are associated with higher
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urinary albumin loss. Although it is generally well known
that elevated albumin excretion is found more frequently
in men than women, this difference is age dependent. Uri-
nary albumin excretion is significantly higher in men than
women, especially at older age [43]. In line with a dif-
ference in albumin excretion between men and women,
GFR is also higher in men than women. With respect to
low birth weight, an inverse association between microal-
buminuria and height was found, arguing that factors
operating in utero or early childhood influence urinary
albumin excretion in later life.
Modifiable factors that have been well documented
in relation to albuminuria
Diabetes. Both glomerular hyperfiltration and a
slightly elevated albumin excretion rate have been found
to predict progressive renal failure in both type 1 [44–
47] and type 2 diabetes [48]. Interestingly, an elevated
albumin excretion not only indicates an increased risk
for renal failure, but also for cardiovascular disease. In-
deed, albuminuria in both type 1 [49] and type 2 [50]
diabetes is associated with widespread endothelial dys-
function, manifest not only in the glomerular vasculature,
but in other vascular beds as well. The prevalence of mi-
croalbuminuria in diabetes has been found to vary from
15% to 30%, depending on the group of subjects studied.
In addition, it has been shown that diabetic nephropathy
progresses more rapidly in men than in women and in
those of low birth weight [51].
Hypertension. Increased urinary albumin loss has also
been linked to essential hypertension [52, 53], with preva-
lences ranging from 10% to 20%. Just as in diabetes, mi-
croalbuminuria in essential hypertension has been taken
to reflect widespread endothelial dysfunction [54]. Albu-
minuria in essential hypertension is associated not only
with left ventricular hypertrophy, but also with glomeru-
lar hyperfiltration [55]. Because microalbuminuric
hypertensive subjects did not show renal vasodilatation
in response to captopril as did normoalbuminuric con-
trols, microalbuminuria may serve as a marker of early
intrarenal vascular dysfunction [56]. In essential hyper-
tension, just as in diabetes, albuminuria predicts both
cardiovascular events and a decline in GFR. Indeed, es-
sential hypertensive subjects with microalbuminuria have
a greater fall in GFR over a 7-year follow-up than do hy-
pertensive subjects without microalbuminuria [57].
Obesity. Elevated albumin excretion is frequently
found in nondiabetic obese subjects [37, 58, 59]. In a group
of more than 200 subjects with a body mass index of
>27 kg/m2, microalbuminuria was found in 12% com-
pared to 3% of a control lean group. The percentage was
even higher (19.2%) when hypertension coexisted with
obesity [58]. In obese subjects, the risk for glomerular
hyperfiltration [58, 59] and hyperperfusion [60] is also
enhanced. This risk for glomerular hyperfiltration seems
to be especially evident in cases of abdominal obesity [58,
48]. The time course of the renal function changes in obe-
sity has thus far only been documented in animal exper-
iments. In a rat model with genetic obesity, an increased
GFR was found. Later in the course, GFR tended to nor-
malize and, subsequently, to decrease together with the
development of progressive albuminuria and glomeru-
losclerosis [61]. In this respect, it is of interest that the
risk for having an impaired GFR is also especially en-
hanced in central obesity: there exists a dose-dependent
relation between waist-to-hip ratio and the risk for an
impaired glomerular filtration rate [59]. The renal conse-
quences of obesity have drawn the attention of clinicians
as obesity-related glomerulopathy [62].
Smoking. Smoking is also associated with an increased
risk for albuminuria, both in diabetic [63] and nondiabetic
[37, 64, 65] subjects. The PREVEND study data showed
that heavy smoking is independently and equally strongly
associated with an increased risk for microalbuminuria
(30–300 mg/day) and for a high normal albumin excre-
tion (15–30 mg/day) compared to the control group with
an albumin excretion of 0 to 15 mg/day [65]. This finding
supports that smoking may be one of the initial triggers
for subsequent albuminuria, but which needs further am-
plifying factors, such as diabetes, hypertension, and/or
obesity.
It has also been documented that smoking may result
in glomerular hyperfiltration, both in diabetic [66] and
nondiabetic subjects [65, 67], although glomerular hyper-
filtration was not found in other epidemiologic studies
[68]. It may well be that initially hyperfiltration exists,
but with a longer duration of the smoking habit, GFR
declines. Indeed, it was shown that smoking is associated
with an increased risk for both hyperfiltration and im-
paired filtration [65]. Lifetime tobacco exposure, but not
current level of smoking, is associated with renal function
impairment and proteinuria [69].
Association between microalbuminuria and the insulin
resistance syndrome. Microalbuminuria in nondiabetic
subjects has been argued to be part of the insulin resis-
tance syndrome [70, 71]. As described above, the various
factors known to be associated with microalbuminuria,
that is, hypertension, hyperglycemia, and obesity, are
well-known components of the insulin resistance syn-
drome. Hypertriglyceridemia, also part of the insulin re-
sistance syndrome, similarly is independently associated
with microalbuminuria [37, 70]. Taking these findings
together, one could argue that insulin resistance is the
underlying pathophysiologic mechanism to explain the
associations between all of the above-mentioned risk fac-
tors and microalbuminuria. In a study using the hyper-
glycemic clamp technique to measure insulin sensitiv-
ity, however, no association was found between insulin
sensitivity and microalbuminuria [72]. Of interest, is the
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finding that hyperinsulinemia is associated with glomeru-
lar hyperfiltration [73].
Modifiable factors which are likely to be related
to albuminuria
Hypercholesterolemia. Some studies found no inde-
pendent association between hypercholesterolemia and
elevated albumin excretion [37, 40]. The Gubbio Study,
however, showed that the risk for elevated albumin ex-
cretion increased 2-fold for each 40 mg/dL increase in
plasma cholesterol [64]. Moreover, it has been shown that
hypertensive subjects with high cholesterol levels have a
more rapid decline in GFR over time [74].
Dietary salt intake. A higher salt intake is indepen-
dently associated with a higher urinary albumin excretion
[75]. Interestingly, a higher salt intake has also been as-
sociated with an increase in GFR, both in normotensive
and hypertensive subjects [76]. The finding that salt in-
take may influence albumin excretion independently of
salt-induced effects on blood pressure is in line with re-
cent data that a high salt intake independently predicts
mortality and the risk for coronary disease [77].
Oral contraceptives and hormone replacement therapy.
The use of oral contraceptives [78, 79] and hormone
replacement therapy [78] is also associated with an
enhanced urinary albumin excretion. Interestingly, the
subjects using such agents also had an elevated creati-
nine clearance [78]. Users of oral contraceptives had an
increased renal vascular resistance and filtration fraction
[80].
DETECTION OF SUBJECTS AT RISK FOR
PROGRESSIVE RENAL FUNCTION LOSS
We have thus shown that not only diabetes and hy-
pertension, but also other factors, such as obesity and
smoking, as well as dietary salt and protein, may induce
glomerular hyperfiltration and enhanced urinary albu-
min excretion in otherwise healthy subjects, and may
thus be related to future progressive renal function loss.
We next should question the magnitude of the problem.
In the previous paragraphs we showed that the preva-
lence of microalbuminuria in relation to various risk fac-
tors is more or less comparable to that seen in diabetes
and hypertension. How many subjects, however, have
an elevated urinary albumin loss that is not due to di-
abetes or hypertension? In a study in more than 40,619
Caucasian subjects, Hillege found 3200 subjects with an
albumin excretion in the microalbuminuric or macropro-
teinuric range (=7.9%). Of this group with albuminuria,
2311 (72.2%) were not known to have diabetes or hy-
pertension. In other words, they, in fact, had unexplained
albuminuria [40]. These figures are comparable to those
of the CARDIA study, which also showed that 70% of
Table 2. Values representing suspected and elevated levels of
albuminuria
Unit Gender Suspected Elevated
24-hour UAEa mg alb/24hr Both 15–30 >30
Timed overnight lg alb/min Both 10–20 >20
sample
Spot morning AC mg alb/g creat Male 10–17 >17
ratiob
Female 15–25 >25
aUAE, urinary albumin excretion in mg/day; no difference for values between
men and women.
bAC ratio, the ratio between albumin (mg/L) and creatinine (g/L) concentra-
tion in the urine.
persons with increased albumin excretion are both nor-
moglycemic and normotensive [81].
Does this imply that we will have to screen the en-
tire population for the presence of albuminuria? One
approach might be to simply do first a dipstick test for
albuminuria on a morning spot urine sample. It has the
advantage of being simple and relatively inexpensive. Be-
cause it may have excess of false positive, but not of false
negative results, it may limit further testing to only those
with a positive test result. In those who screened pos-
itive, further more precise measurements are required.
Although the gold standard for defining whether there
is an elevated urinary albumin excretion remains one
(or preferably more) 24-hour urine sample(s), in daily
practice a spot morning urine sample for measurement
of albumin and creatinine excretion is frequently used.
Recently, an accurate and immediately available quan-
titative determination of the urinary albumin-to-
creatinine ratio has been introduced [82]. Although
simple to obtain, this test has the disadvantage
that the resulting albumin/creatinine ratio may in-
correctly suggest elevated albumin excretion merely
because the subject has a low creatinine excretion due to
reduced muscle mass, as is the case in women or elderly. If
24-hour urine sampling is not possible, a timed overnight
urine sample may also be preferable to a spot morning
sample. A timed sample is not especially cumbersome, as
it only requires denoting the time of the actual and previ-
ous voiding, and has the advantage over the spot sample
of allowing estimation of the rate of albumin excretion.
Table 2 indicates the generally accepted cut-off values
for the definitions of microalbuminuria. Since there is no
precise lower cut-off below which there is no increased
risk [83, 84], and since there is also no known upper limit
above which the risk ceases to exponentially rise, we
prefer not to categorize according to the magnitude of
albuminuria (that is, micro- vs. macroalbuminuria), but
simply to screen for detection and quantification.
It could be questioned whether screening of the entire
population is worth the effort because albuminuria will
be found only in 2.2% to 10.2% of the general population,
depending on the population screened, the age of the sub-
jects, etc. Perhaps better than screening the entire popu-
lation, it could be advocated to screen those subjects aged
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25 or older, with any of the cited risk factors: male gender,
low birth weight, diabetes, hypertension, obesity, smok-
ing, and high salt and protein intake. By doing so, we will
be able to identify subjects having not only cardiovascu-
lar and renal risk factors, but those suffering from actual
vascular damage. Indeed, as in diabetes and essential hy-
pertension, an elevated albumin excretion indicates not
only progressive renal [85], but also cardiovascular dam-
age in the general population [41, 83, 84, 87, 88]. Compar-
ing the various publications, it is of interest to realize that
the impact of microalbuminuria in predicting future renal
and cardiovascular morbidity in these various cohorts is
similar to that seen in subjects with overt diabetes [89] or
hypertension. In all conditions, those with albuminuria
have an approximately 2-fold increased risk; this risk in
an absolute way is, however, less pronounced in nondia-
betics compared to diabetics. Of interest is the study of
Borch-Johnsen et al [87], which showed that the presence
of albuminuria more than doubled the predictive effect
of the conventional atherosclerotic risk factors, be it male
gender, smoking, hypertension, or hypercholesterolemia.
This better prediction of cardiovascular morbidity and
mortality using albuminuria is probably related to the
fact that the albumin leakage in the glomerular vessels is
really an expression of generalized vascular damage [90].
In this way, an elevated urinary albumin excretion may
thus be considered the reflection of early atherosclerosis.
WHAT THERAPY SHOULD BE INSTITUTED
FOR PRIMARY PREVENTION OF RENAL
DISEASE?
As already indicated, secondary prevention of progres-
sive renal function loss in those with preexisting renal
disease currently involves such therapies as dietary pro-
tein and salt restriction, and intervention in the renin-
angiotensin-angiotensinogen system (RAAS) with either
ACE inhibitors or angiotensin II receptor antagonists,
along with other antihypertensives, if needed. The effi-
cacy of various approaches in primary prevention of both
development and progression of albuminuria is less well
defined. Although there are some studies that report that
progression of microalbuminuria can be halted in dia-
betic subjects with strict control of plasma glucose levels
[91, 92], ACE inhibition [93, 94], and angiotensin II re-
ceptor antagonism [94–97], real primary prevention trials
showing that the progression of normoalbuminuria to mi-
croalbuminuria can be prevented are even more scarce.
Strict glucose control has been shown both in type 1 [98]
and type 2 [99] diabetics to slow the increase in the level
of albuminuria, and to postpone the occurrence of overt
diabetic nehropathy. Of special interest are the data of
the DCCT trial [98], which showed that intensive insulin
treatment prevented the development of microalbumin-
uria both in the primary prevention and the secondary
intervention cohort to approximately similar extent (e.g.,
by 34% and 43%, respectively).
Ravid et al [100] studied the effect of ACE inhibitors
to prevent the rise in albuminuria and the fall in GFR in
normotensive normoalbuminuric type 2 diabetics. They
showed that enalapril reduced the transition from normo-
to microalbuminuria from 19% on placebo to 6.5% on
enalapril during a 6-year follow-up in type 2 diabet-
ics. The fall in creatinine clearance was less marked in
the enalapril-treated patients. The Euclid study group
showed that an ACE inhibitor prevented the rise in al-
buminuria more effectively than placebo, although this
beneficial effect was more pronounced (49.7%) in the
subjects with microalbuminuria at baseline than in the
subjects with an albumin excretion in the high-normal
(5–10 or 10–20 lg/min) range (e.g., 21.3% and 18.8%, re-
spectively) [101]. Also encouraging are studies showing
regression of microalbuminuria both in type 1 [102] and
type 2 [95, 96] diabetic patients.
Some data have been have published on the effects
of lipid-lowering drugs on urinary albumin loss and reno-
protection in diabetes. Although a review of older studies
questioned the efficacy of statins to confer renoprotection
[103], more recent reports favor some optimism, since
statins have been found to lower albuminuria both in nor-
motensive [104] and hypertensive [105] dyslipidemic type
2 diabetic subjects, as well as in patients with familial hy-
percholesterolemia [106]. This reduction of albumin loss
seems in large part to be independent of the reduction
of low-density lipoprotein (LDL) cholesterol. It has sim-
ilarly been shown that lowering of plasma triglycerides
with gemfibrozil in type 2 diabetic subjects improves uri-
nary albumin excretion [107].
Also of interest are recent data showing that the
oral glycosaminoglycan sulodexide improves albumin-
uria both in type 1 [108, 109] and type 2 [109] diabetes. The
effect was also manifest in patients who were already on
ACE inhibitors, which suggests an additive effect. Stud-
ies designed to evaluate the long-term effects of statins,
fibrates, or sulodexide on progression of normo- to albu-
minuria have, however, yet to be reported.
Some data are available on primary prevention in es-
sential hypertension. It has been shown that blood pres-
sure lowering with an ACE inhibitor is more effective
than a diuretic, a beta-blocking agent, or a calcium en-
try blocker to lower albumin excretion in essential hy-
pertension [110]. It is more difficult to draw conclusions
regarding the long-term effects of antihypertensive reg-
imens on progression of albuminuria and on renal func-
tion decline. Aurell et al [111] found no difference in a
6-year treatment course with an ACE inhibitor or a beta-
blocking agent on the change in GFR in essential hy-
pertensive subjects with a baseline GFR of >80 mL/min.
On both drugs the blood pressure treatment goal was
reached, and in both groups the decline in GFR was
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1 mL/min/year, which is comparable to the GFR decline
observed in normal subjects. Adequate blood pressure
lowering is thus probably of more importance than the
type of drug used. That study unfortunately did not re-
port on albumin excretion. Whether ACE inhibitors and
statins will lower urinary albumin excretion and prevent
renal function decline in albuminuric, but nonhyperten-
sive and nonhyperlipidemic subjects, is presently under
investigation in the PREVEND study [112].
Some studies report on the effects of weight reduction
on urinary albumin loss in obese subjects. It was shown
that a diet low in calories improves urinary albumin loss
and GFR in obese diabetic [113] and hypertensive [114]
subjects.
Although a cross-sectional study showed subjects who
quit smoking to have a lower albumin loss than those
that were still smoking [65], a prospective study could not
demonstrate a beneficial effect of smoking cessation on
albumin excretion, at least not in subjects with an albumin
excretion in the normal range [115].
CONCLUSION
In recent years, more and more subjects present with
end-stage renal failure without known prior renal disease.
Such subjects could undoubtedly be detected in an earlier
phase by screening for albuminuria. Urinary albumin loss
is an indicator of poor renal, as well as poor cardiovas-
cular, prognosis. Not only are diabetic subjects at risk for
albuminuria, but also hypertensive, obese, and smoking
subjects. Men at older age, and with a low birth weight,
are especially at risk, while such exogenous factors as
high salt and protein intake, as well as hormone replace-
ment therapy in women, also enhance the risk. Therapies
that have been shown to lower albumin excretion, such as
ACE inhibitors, angiotensin II receptor antagonists, and
statins should be started early in such patients to pre-
vent them from reaching end-stage renal failure. In this
way, we believe the present practice of secondary pre-
vention in those with known prior renal disease should
be extended to primary prevention for those subjects in
the general population who are at risk for progressive
renal failure, including those with high-normal albumin
excretion rates.
In carrying out this early attempt to marshal evidence
in support of a screening initiative based on albuminuria,
the authors recognize that many areas relating to pre-
ventive therapy will require far more outcomes-based
evidence than now exists. Indeed, our goal has been to
draw attention not only to these relatively few modali-
ties of therapy that may already be regarded as proven,
but to identify the more numerous areas where defini-
tive evidence of efficacy and safety is still lacking. We
recognize, too, that any fruitful discussion relating to
primary prevention must also consider such important
factors as health manpower resources, other competing
public health priorities, economics and cost-effectiveness
issues, and the general applicability of the present dis-
cussion to first versus third world health care systems
[116]. It is hoped that this review will spur others to aug-
ment the level of dialogue, and to carry out epidemiologic
and clinical outcome studies needed to permit a forward
thrust in this heretofore-neglected area of chronic disease
prevention.
NOTE ADDED IN PROOF
After acceptance of this manuscript, the results of the PREVEND in-
tervention trial have been published. Treatment with an ACE inhibitor,
but not a statin, lowered albuminuria persistently over a 4-year period in
subjects with an elevated albuminuria but relatively normal blood pres-
sure and serum cholesterol levels. The lowering of albuminuria on the
ACE inhibitor was associated with fewer cardiovascular events [117].
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